Genetic liability to critically ill COVID-19 increased risk of HER2-positive breast cancer through the immune pathway: A Mendelian randomization study.

ABSTRACT: The clinical management of patients with both coronavirus disease 2019 (COVID-19) and breast cancer remains a complex and unresolved issue that despite extensive discussion has not reached a consensus. In contemporary literature, the association between COVID-19 and HER2-positive breast cancer has received minimal attention. Genetic instruments for severe acute respiratory syndrome coronavirus 2 infection (N = 2,597,856), hospitalized COVID-19 (N = 2,095,324), and critically ill COVID-19 (N = 1,086,211) were obtained from the COVID-19 Host Genetics Initiative genome-wide association study (GWAS) meta-analysis. A total of 103,530 HER2-positive breast cancer cases from GWAS were enrolled in our study. The summary GWAS statistics of 731 immune cells (N = 3757) were obtained from the MRCEU ope

SUBMITTER: Chen J 

PROVIDER: S-EPMC12074039 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature